Emilumenib

Emilumenib is an orally bioavailable small molecule inhibitor of menin, with potential antineoplastic activity. Upon oral administration, emilumenib targets and binds to the nuclear protein menin, thereby preventing the interaction between the two proteins menin and menin-mixed lineage leukemia (MLL; myeloid/lymphoid leukemia; KMT2A) and the formation of the menin-MLL complex. This reduces the expression of downstream target genes and results in an inhibition of the proliferation of MLL-rearranged leukemic cells. The menin-MLL complex plays a key role in the survival, growth, transformation and proliferation of certain kinds of leukemia cells. The directory classifies it as a clinical API with a synthetic source/manufacturing origin. Other names for this substance include DS-1594B and Menin-MLL inhibitor 26. Its PubChem CID is 146636100.

CAS No 2440018-29-9
Molecular Formula C27H29F3N6O3S
Molecular Weight 574.6 g/mol
Synonyms (1R,2S,4R)-4-[[4-(5,6-dimethoxypyridazin-3-yl)phenyl]methylamino]-2-[methyl-[6-(2,2,2-trifluoroethyl)thieno[2,3-d]pyrimidin-4-yl]amino]cyclopentan-1-ol

Frequently Asked Questions